NEWS

03/16/2023

Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

03/09/2023

Immunome to Present at 13th Annual World ADC London Conference

02/08/2023

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

01/06/2023

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

11/14/2022

Immunome Reports Third Quarter 2022 Financial Results

11/09/2022

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

11/07/2022

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

08/23/2022

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

08/05/2022

Immunome Reports Second Quarter 2022 Financial Results

07/06/2022

Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1